• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·ZTS
Share

Zoetis Inc. Stocks

$ 77.59Last Updated 03.06.2026

Issuer Rating

6/7
Performance

Favourable

Risk

Low

Recommendation

Buy

Market Cap

$ 32.56B

$ 77.59
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Latest news

04.06.2026 18:29

From Palantir to Nvidia: what "sand castles" Burry has found in AI rallying

19.05.2026 23:35

Adobe, Zoetis and PayPal: an investor from The Big Short bought stocks outside the AI bubble

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. Specifically, the stock is 'cheap' on P/E, neutral on EV/EBITDA, reasona

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of ZTS is 129 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

04.06.2026 20:07

On the same rake: Bill Ackman sees AI rally as a repeat of investors' mistake of 2000

04.06.2026 19:55

Pirelli shares fall 13% after shortseller accused of ties to Russian army

04.06.2026 19:12

"A revolution in the communications segment": why an analyst saw a threat to AT&T in Starlink satellites

04.06.2026 18:29

From Palantir to Nvidia: what "sand castles" Burry has found in AI rallying

04.06.2026 17:50

Motley Fool analyst flags potential 'great entry point' for e.l.f. Beauty

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026